Drug Interaction Report
3 potential interactions and/or warnings found for the following 2 drugs:
- levofloxacin
- Proben-C (colchicine / probenecid)
Interactions between your drugs
probenecid levoFLOXacin
Applies to: Proben-C (colchicine / probenecid), levofloxacin
Probenecid has been shown to interfere with the urinary excretion of certain quinolone antibiotics, resulting in increased plasma quinolone concentrations in some cases. The clinical relevance of this interaction is unknown but may be greater for quinolones that undergo significant tubular secretion via the renal anion transporter system such as cinoxacin, ciprofloxacin, enoxacin, gemifloxacin, nalidixic acid, and norfloxacin. In one study, serum levels of cinoxacin reportedly doubled in the presence of probenecid, while urinary recovery in a 7-hour period was reduced by 32%. In another study (n=12), mean systemic exposure (AUC) of a 200 mg IV dose of ciprofloxacin increased by 75% and renal clearance decreased by 64% following pretreatment with multiple-dose probenecid. Likewise, probenecid has been found to reduce renal clearance of enoxacin and gemifloxacin by approximately 50%. Another study reported a threefold increase in the peak serum nalidixic acid level of two volunteers 8 hours following coadministration of a 500 mg dose of nalidixic acid and a 500 mg dose of probenecid. Also, a 1 gram dose of probenecid reduced the 12-hour urinary recovery of a single 200 mg dose of norfloxacin by about one-half in five study subjects, although serum concentrations were not significantly changed. In contrast, probenecid appears to have no clinically significant effect on the pharmacokinetics of moxifloxacin, ofloxacin, or sparfloxacin. In general, no precautions appear to be necessary during coadministration of most quinolones and probenecid. However, in the treatment of urinary tract infections, clinicians should consider the possibility of reduced antibacterial efficacy due to decreased quinolone excretion into the urine.
References (11)
- Wijnands WJ, Vree TB, Baars AM, van Herwaarden CL (1988) "Pharmacokinetics of enoxacin and its penetration into bronchial secretions and lung tissue." J Antimicrob Chemother, 21, p. 67-77
- Shimada J, Yamaji T, Ueda Y, Uchida H, Kusajma H, Irikura T (1983) "Mechanism of renal excretion of AM-715, a new quinolonecarboxylic acid derivative, in rabbits, dogs, and humans." Antimicrob Agents Chemother, 23, p. 1-7
- Weidekamm E, Portmann R, Suter K, et al. (1987) "Single- and multiple-dose pharmacokinetics of fleroxacin, a trifluorinated quinolone, in humans." Antimicrob Agents Chemother, 31, p. 1909-14
- Rodriguez N, Madsen PO, Welling PG (1979) "Influence of probenecid on serum levels and urinary excretion of cinoxacin." Antimicrob Agents Chemother, 15, p. 465-9
- (2001) "Product Information. Noroxin (norfloxacin)." Merck & Co., Inc
- Dash H, Mills J (1976) "Letter: Severe metabolic acidosis associated with nalidixic acid overdose." Ann Intern Med, 84, p. 570-1
- Jaehde U, Sorgel F, Reiter A, Sigl G, Naber KG, Schunack W (1995) "Effect of probenecid on the distribution and elimination of ciprofloxacin in humans." Clin Pharmacol Ther, 58, p. 532-41
- Shimada J, Nogita T, Ishibashi Y (1993) "Clinical pharmacokinetics of sparfloxacin." Clin Pharmacokinet, 25, p. 358-69
- Nataraj B, Mamidi NVSR, Krishna DR (1998) "Probenecid affects the pharmacokinetics of ofloxacin in healthy volunteers." Clin Drug Invest, 16, p. 259-62
- Stass H, Sachse R (2001) "Effect of probenecid on the kinetics of a single oral 400mg dose of moxifloxacin in healthy male volunteers." Clin Pharmacokinet, 40 Suppl 1, p. 71-6
- (2003) "Product Information. Factive (gemifloxacin)." *GeneSoft Inc
Drug and food/lifestyle interactions
colchicine food/lifestyle
Applies to: Proben-C (colchicine / probenecid)
GENERALLY AVOID: Coadministration with grapefruit juice may increase the serum concentrations of colchicine. Clinical toxicity including myopathy, neuropathy, multiorgan failure, and pancytopenia may occur. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism and P-glycoprotein efflux in the gut wall by certain compounds present in grapefruits. A published case report describes an eight-year-old patient with familial Mediterranean fever who developed acute clinical colchicine intoxication after ingesting approximately one liter of grapefruit juice per day for two months prior to hospital admission while being treated with colchicine 2 mg/day. Her condition progressed to circulatory shock and multiorgan failure, but she recovered with supportive therapy after 24 days in the hospital. In a study of 21 healthy volunteers, administration of 240 mL grapefruit juice twice a day for 4 days was found to have no significant effect on the pharmacokinetics of a single 0.6 mg dose of colchicine. However, significant interactions have been reported with other CYP450 3A4 inhibitors such as clarithromycin, diltiazem, erythromycin, ketoconazole, ritonavir, and verapamil.
MANAGEMENT: Patients treated with colchicine should be advised to avoid the consumption of grapefruit and grapefruit juice, and to contact their physician if they experience symptoms of colchicine toxicity such as abdominal pain, nausea, vomiting, diarrhea, fatigue, myalgia, asthenia, hyporeflexia, paresthesia, and numbness.
References (19)
- Pettinger WA (1975) "Clonidine, a new antihypertensive drug." N Engl J Med, 293, p. 1179-80
- Caraco Y, Putterman C, Rahamimov R, Ben-Chetrit E (1992) "Acute colchicine intoxication: possible role of erythromycin administration." J Rheumatol, 19, p. 494-6
- Schiff D, Drislane FW (1992) "Rapid-onset colchicine myoneuropathy." Arthritis Rheum, 35, p. 1535-6
- Putterman C, Ben-Chetrit E, Caraco Y, Levy M (1991) "Colchicine intoxication: clinical pharmacology, risk factors, features, and management." Semin Arthritis Rheum, 21, p. 143-55
- Boomershine KH (2002) "Colchicine-induced rhabdomyolysis." Ann Pharmacother, 36, p. 824-6
- (2003) "Severe colchicine-macrolide interactions." Prescrire Int, 12, p. 18-9
- Tateishi T, Soucek P, Caraco Y, Guengerich FP, Wood AJ (1996) "Colchicine biotransformation by human liver microsomes. Identification of CYP3A4 as the major isoform responsible for colchicine demethylation." Biochem Pharmacol, 53, p. 111-6
- Dogukan A, Oymak FS, Taskapan H, Guven M, Tokgoz B, Utas C (2001) "Acute fatal colchicine intoxication in a patient on continuous ambulatory peritoneal dialysis (CAPD). Possible role of clarithromycin administration." Clin Nephrol, 55, p. 181-2
- Rollot F, Pajot O, Chauvelot-Moachon L, Nazal EM, Kelaidi C, Blanche P (2004) "Acute colchicine intoxication during clarithromycin administration." Ann Pharmacother, 38, p. 2074-7
- Wilbur K, Makowsky M (2004) "Colchicine myotoxicity: case reports and literature review." Pharmacotherapy, 24, p. 1784-92
- Hung IF, Wu AK, Cheng VC, et al. (2005) "Fatal interaction between clarithromycin and colchicine in patients with renal insufficiency: a retrospective study." Clin Infect Dis, 41, p. 291-300
- Cheng VC, Ho PL, Yuen KY (2005) "Two probable cases of serious drug interaction between clarithromycin and colchicine." South Med J, 98, p. 811-3
- Akdag I, Ersoy A, Kahvecioglu S, Gullulu M, Dilek K (2006) "Acute colchicine intoxication during clarithromycin administration in patients with chronic renal failure." J Nephrol, 19, p. 515-7
- van der Velden W, Huussen J, Ter Laak H, de Sevaux R (2008) "Colchicine-induced neuromyopathy in a patient with chronic renal failure: the role of clarithromycin." Neth J Med, 66, p. 204-6
- Goldbart A, Press J, Sofer S, Kapelushnik J (2000) "Near fatal acute colchicine intoxication in a child. A case report." Eur J Pediatr, 159, p. 895-7
- (2008) "Colchicine: serious interactions." Prescrire Int, 17, p. 151-3
- (2009) "Product Information. Colcrys (colchicine)." AR Scientific Inc
- Dahan A, Amidon GL (2009) "Grapefruit juice and its constitueants augment colchicine intestinal absorption: potential hazardous interaction and the role of p-glycoprotein." Pharm Res, 26, p. 883-92
- McKinnell J, Tayek JA (2009) "Short term treatment with clarithromycin resulting in colchicine-induced rhabdomyolysis." J Clin Rheumatol, 15, p. 303-5
levoFLOXacin food/lifestyle
Applies to: levofloxacin
ADJUST DOSING INTERVAL: Food may reduce the oral absorption and bioavailability of levofloxacin. According to the drug product labeling, administration of levofloxacin 500 mg with food prolonged the time to peak concentration by 1 hour and decreased the Cmax decreased by 25% following administration of the oral solution and by 14% following administration of the oral tablet.
MANAGEMENT: To ensure maximal and consistent oral absorption, levofloxacin oral solution should be taken at least one hour before or two hours after meals. For administration of the oral solution with continuous enteral nutrition, some experts recommend that the tube feeding should be interrupted for one hour before and two hours after the dose of levofloxacin. The oral tablets may be taken without regard to food.
References (1)
- Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT (2009) "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm, 66, p. 1438-67
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Cefdinir
Cefdinir is used for bacterial infection, bronchitis, middle ear infections, pneumonia, sinusitis ...
Amoxicillin/clavulanate
Amoxicillin and clavulanate potassium is a combination antibiotic used to treat bacterial ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Clindamycin
Clindamycin (Cleocin) is used to treat serious infections caused by bacteria. Includes clindamycin ...
Augmentin
Augmentin is a prescription antibiotic combining amoxicillin and clavulanate to treat bacterial ...
Cephalexin
Cephalexin is a cephalosporin antibiotic used to treat bacterial infections like respiratory, skin ...
Ceftriaxone
Ceftriaxone is used for bacteremia, bacterial endocarditis prevention, bacterial infection, bone ...
Metronidazole
Metronidazole is an antibiotic used to fight bacteria in your body. Learn about side effects ...
Ciprofloxacin
Ciprofloxacin is an antibiotic belong to a group of drugs called fluoroquinolones. Learn about side ...
Doxycycline
Doxycycline is a tetracycline antibiotic used to treat many different bacterial infections such as ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.